Business Description
ChemoCentryx Inc
NAICS : 541714
SIC : 2834
ISIN : US16383L1061
Description
ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.56 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 9.81 | |||||
| Beneish M-Score | 11.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -19 | |||||
| 3-Year EBITDA Growth Rate | -35.4 | |||||
| 3-Year EPS without NRI Growth Rate | -35.5 | |||||
| 3-Year Book Growth Rate | 140.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 148.08 | |||||
| 12-1 Month Momentum % | 48.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.54 | |||||
| Quick Ratio | 4.47 | |||||
| Cash Ratio | 4.32 | |||||
| Days Inventory | 1113.11 | |||||
| Days Sales Outstanding | 55.81 | |||||
| Days Payable | 2554.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.6 | |||||
| Shareholder Yield % | -0.36 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 97.29 | |||||
| Operating Margin % | -353.93 | |||||
| Net Margin % | -357.78 | |||||
| FCF Margin % | -158.52 | |||||
| ROE % | -46.62 | |||||
| ROA % | -30.14 | |||||
| ROIC % | -77.79 | |||||
| ROC (Joel Greenblatt) % | -228.74 | |||||
| ROCE % | -34.65 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 98.47 | |||||
| PB Ratio | 15.68 | |||||
| Price-to-Tangible-Book | 15.66 | |||||
| EV-to-EBIT | -26.67 | |||||
| EV-to-EBITDA | -27.52 | |||||
| EV-to-Revenue | 93.62 | |||||
| EV-to-Forward-Revenue | 18.94 | |||||
| EV-to-FCF | -59.06 | |||||
| Price-to-Net-Current-Asset-Value | 22.8 | |||||
| Price-to-Net-Cash | 25.49 | |||||
| Earnings Yield (Greenblatt) % | -3.75 | |||||
| FCF Yield % | -1.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CCXI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ChemoCentryx Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 37.2 | ||
| EPS (TTM) ($) | -1.89 | ||
| Beta | 0 | ||
| Volatility % | 159.77 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR ($) | 0.068929 | ||
| 20-Day SMA ($) | 0 | ||
| 12-1 Month Momentum % | 48.64 | ||
| 52-Week Range ($) | 14.95 - 52 | ||
| Shares Outstanding (Mil) | 71.92 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ChemoCentryx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ChemoCentryx Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ChemoCentryx Inc Frequently Asked Questions
What is ChemoCentryx Inc(CCXI)'s stock price today?
The current price of CCXI is $51.99. The 52 week high of CCXI is $52.00 and 52 week low is $14.95.
When is next earnings date of ChemoCentryx Inc(CCXI)?
The next earnings date of ChemoCentryx Inc(CCXI) is .
Does ChemoCentryx Inc(CCXI) pay dividends? If so, how much?
ChemoCentryx Inc(CCXI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers